Business
Kezar to Host Virtual Investor and Analyst Day on November 15, 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing
About this update from Kezar Life Sciences, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nKezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a virtual Investor and Analyst Day on November 15, 2021, at 4:30 p.m. ET.\n\nThe event will highlight KZR-616, including interim data from Kezar’s MISSION study, an open-label Phase 2 trial in patients with active, proliferative lupus nephritis and, also feature a presentation from Samir V. Parikh, MD, Assistant Professor of Medicine, Nephrology, The Ohio State University Medical Center. Additionally, the Company will present an overview of their protein secretion drug discovery platform and lead candidate, KZR-261, a novel, broad-spectrum, anti-tumor agent that acts through direct interaction and inhibition of the Sec61 translocon. Details will be provided around the Phase 1 trial design, KZR-261-101, evaluating safety, tolerability, and preliminary tumor activity, as well as the tumor selection process.\n\nPresenters:\n\n\nJohn Fowler, Chief Executive Officer, Co-Founder\n\n\nNoreen Roth Henig, M.D., Chief Medical Officer\n\n\nSamir V. Parikh, M.D., Assistant Professor of Medicine, Division of Nephrology, The Ohio State University Medical Center.\n\n\nChristopher Kirk, Ph.D., President and Chief Scientific Officer, Co-Founder\n\n\nThe presentation will be followed by a Q&A session.\n\nTo register for this event, please go to: https://kvgo.com/corporate-services/kezar-kol-day-2021\n\nA live webcast of the event can be found on the Kezar website at www.kezarlifesciences.com/investors/news-events. A replay of the event will be available for 90 days following the presentation.\n\nAbout KZR-616\n\nKZR-616 is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from Phase 1a and 1b clinical trials provide evidence that KZR-616 exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. Phase 2 trials are underway in multiple severe auto...